SCHEMBL27247273

SCHEMBL27247273

C=C(C)c1cc2cc(CNC(=O)O)n(S(=O)(=O)c3ccc(C)cc3)c2cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1B P49286 1/20 0.45
▸ PPARG P37231 6/20 0.42
▸ PPARD Q03181 3/20 0.42
▸ PPARA Q07869 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PKM P14618 4/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NOD1 Q9Y239 2/20 0.37
▸ NOD2 Q9HC29 1/20 0.37
▸ RAB9A P51151 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30920593 0.89 MTNR1B (0.40) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL27247942 0.84 MTNR1B (0.46) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL27247669 0.83 MTNR1B (0.46) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL27246722 0.83 MTNR1B (0.46) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL27247546 0.83 MTNR1B (0.47) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL30920598 0.81 MTNR1B (0.42) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL30920412 0.80 MTNR1B (0.41) MTNR1BPPARGPPARDPPARAKDM4E
Hydrochloric Acid SCHEMBL27247073 0.77 KDM4E (0.44) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL27247879 0.76 PPARG (0.46) MTNR1BPPARGPPARDPPARAKDM4E
SCHEMBL31335990 0.75 KDM4E (0.50) KDM4ELMNATSHRL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 MTNR1B 111/4885PPARG 4723/4885PPARD 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback